Lusutrombopag's metabolism is significantly influenced by the CYP4A11 gene, with genetic variations affecting how quickly the drug is metabolized, and thus its levels and effectiveness. Additionally, genes ABCB1 and ABCG2, encoding transport proteins, impact the drugâ€™s absorption and excretion, altering its bioavailability and required dosage. These interactions are crucial for optimizing treatment effectiveness and minimizing adverse effects in individuals.